Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 5,918,076.94, a significant increase of 144.50% year-over-year[11]. - Operating revenue for Q1 2023 reached CNY 66,131,447.53, reflecting a growth of 0.94% compared to the same period last year[11]. - The weighted average return on net assets attributable to shareholders was 1.20%, up from 0.79% in the previous year[11]. - Total operating revenue for Q1 2023 was CNY 66,131,447.53, a slight increase from CNY 65,517,072.24 in Q1 2022, representing a growth of 0.94%[40]. - Net profit for Q1 2023 reached CNY 5,918,076.94, up 144.00% from CNY 2,420,478.76 in Q1 2022[41]. - Basic and diluted earnings per share for Q1 2023 were CNY 0.0838, compared to CNY 0.0445 in Q1 2022, an increase of 88.53%[41]. - Total comprehensive income for Q1 2023 was CNY 5,918,076.94, compared to CNY 2,420,478.76 in Q1 2022, reflecting a growth of 144.00%[41]. Cash Flow - The net cash flow from operating activities surged by 1,764.60% to CNY 13,567,751.15, driven by increased accounts receivable collections[13]. - Cash flow from operating activities totaled 72,632,647.13 in Q1 2023, an increase of 19.0% from 61,018,964.07 in Q1 2022[48]. - The company achieved a net cash inflow from investment activities of CNY 155,954,166.66 in Q1 2023, compared to CNY 20,000.00 in Q1 2022[46]. - Cash inflow from financing activities in Q1 2023 was 20,000,000.00, while cash outflow was 394,410.02, resulting in a net cash inflow of 19,605,589.98[49]. - The company ended Q1 2023 with a cash increase of 98,291,180.20, compared to an increase of 3,972,245.79 in Q1 2022[47]. Assets and Liabilities - Total assets as of March 31, 2023, increased by 0.50% to CNY 779,993,778.03 compared to the end of 2022[11]. - Current assets totaled ¥425,680,764.67, showing a marginal decrease from ¥425,902,603.64 at the end of 2022[34]. - Total liabilities decreased to ¥284,718,796.41 from ¥286,721,987.96, reflecting a reduction of about 0.7%[35]. - Current liabilities increased to ¥217,233,622.82 from ¥213,557,988.27, indicating an increase of approximately 1.6%[35]. - Non-current assets totaled ¥354,313,013.36, up from ¥350,176,289.00, marking an increase of about 1%[35]. - The company's equity increased to ¥495,274,981.62 from ¥489,356,904.68, reflecting a growth of approximately 1.9%[36]. Shareholding Structure - The largest shareholder, Xue Xinghan, holds 28,552,989 shares, representing 40.45% of the total shares[19]. - Wang Daoqun is the second-largest shareholder with 10,002,200 shares, accounting for 14.17%[19]. - The total shares held by the top ten shareholders amount to 57,849,301, which is 81.95% of the total shares[22]. - The combined shareholding of Xue Xinghan, Haihuijuzheng, and Weishijuzheng is 51.45%, indicating they are acting in concert[22]. Guarantees and Pledges - The company has a guarantee amount of 40,000,000 yuan with a balance of 28,400,000 yuan for a related party, with the guarantee period starting from July 2020 to July 2027[27]. - The company has provided a guarantee of 20,000,000 yuan with a balance of 17,400,000 yuan for another related party, with the guarantee period from May 2021 to May 2028[28]. - The company has a guarantee of 10,000,000 yuan with a balance of 8,700,000 yuan for a related party, with the guarantee period from September 2021 to September 2028[28]. - The company has a fixed asset mortgage of 126,388,936.74 yuan, which represents 16.20% of total assets[30]. - The company has a pledge of 71,081,881.71 yuan for 100% equity, accounting for 9.11% of total assets[30]. - The company has a pledge of accounts receivable amounting to 43,008,506.60 yuan, which is 5.51% of total assets[30]. Other Financial Metrics - The company's financial expenses decreased by 105.04% year-over-year, primarily due to increased interest income from unused raised funds[13]. - The gross profit margin improved due to a rise in sales of high-margin medical products, with sales of blood glucose and oxygen meter modules increasing significantly[13]. - The company reported a significant increase in other income to CNY 2,766,473.94 in Q1 2023 from CNY 404,804.83 in Q1 2022, an increase of 584.51%[40]. - Research and development expenses decreased to CNY 3,789,382.71 in Q1 2023 from CNY 4,289,517.47 in Q1 2022, a decline of 11.65%[40]. - Investment income for Q1 2023 was CNY 380,530.70, down from CNY 1,005,675.61 in Q1 2022, a decrease of 62.16%[40].
则成电子(837821) - 2023 Q1 - 季度财报